Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors
BioNTech SE
BioNTech SE
Prisma Health-Upstate
Zhejiang University
TCRCure Biopharma Ltd.
Nuvation Bio Inc.
Boundless Bio, Inc.
Innovent Biologics (Suzhou) Co. Ltd.
Gustave Roussy, Cancer Campus, Grand Paris
Eli Lilly and Company
Sanofi
MapKure, LLC
L & L Bio Co., Ltd., Ningbo, China
BioNTech SE
Ono Pharmaceutical Co. Ltd
Memorial Sloan Kettering Cancer Center
Noile-Immune Biotech, Inc
Gilead Sciences
BeiGene
Health Hope Pharma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
OBI Pharma, Inc
Enlivex Therapeutics RDO Ltd.
InteRNA
Debiopharm International SA
Dana-Farber Cancer Institute
ORIC Pharmaceuticals
Bio-Thera Solutions
Gilead Sciences
Athenex, Inc.
Ipsen
Jiangsu HengRui Medicine Co., Ltd.
Lidds AB
Eli Lilly and Company
Adagene Inc
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Spectrum Pharmaceuticals, Inc
Texas Tech University Health Sciences Center, El Paso
St Vincent's Hospital, Sydney
Hoffmann-La Roche
Secretaria de Estado da Saúde
Eli Lilly and Company
Hutchmed
Bristol-Myers Squibb
University of California, San Francisco
Pfizer
Endocyte
Vanderbilt-Ingram Cancer Center